Analysing the ethics of breast cancer overdiagnosis: a pathogenic vulnerability

Medicine, Health Care, and Philosophy
Wendy Rogers

Abstract

Breast cancer screening aims to help women by early identification and treatment of cancers that might otherwise be life-threatening. However, breast cancer screening also leads to the detection of some cancers that, if left undetected and untreated, would not have damaged the health of the women concerned. At the time of diagnosis, harmless cancers cannot be identified as non-threatening, therefore women are offered invasive breast cancer treatment. This phenomenon of identifying (and treating) non-harmful cancers is called overdiagnosis. Overdiagnosis is morally problematic as it leads to overall patient harm rather than benefit. Further, breast cancer screening is offered in a context that exaggerates cancer risk and screening benefit, minimises risk of harm and impedes informed choice. These factors combine to create pathogenic vulnerability. That is, breast cancer screening exacerbates rather than reduces women's vulnerability and undermines women's agency. This paper provides an original way of conceptualising agency-supporting responses to the harms of breast cancer overdiagnosis through application of the concept of pathogenic vulnerability.

References

Jan 1, 1995·Health Affairs·D Chollet
Jun 2, 2001·Medical Decision Making : an International Journal of the Society for Medical Decision Making·E SilvermanB Fischhoff
Feb 13, 2003·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·Suzanne M Johnson Vickberg
Oct 16, 2003·International Journal of Epidemiology·Gianfranco DomenighettiMarcel Zwahlen
Jan 8, 2004·JAMA : the Journal of the American Medical Association·Lisa M SchwartzH Gilbert Welch
Jan 25, 2006·Social Science & Medicine·Juanne N Clarke, Michelle M Everest
Jul 27, 2007·New South Wales Public Health Bulletin·Joanne M Spangaro
Sep 24, 2008·BMJ : British Medical Journal·Vikki A EntwistleGlenn Salkeld
Feb 2, 2010·Critical Reviews in Oncology/hematology·Anja Mehnert
Jun 2, 2010·New South Wales Public Health Bulletin·James R Hales
Sep 10, 2010·The New England Journal of Medicine·Kerianne H Quanstrum, Rodney A Hayward
Mar 30, 2011·Archives of Internal Medicine·Lisa M SchwartzH Gilbert Welch
Apr 26, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lynda M VroomanStephen E Sallan
Jul 5, 2011·Preventive Medicine·Jolyn HerschKirsten McCaffery
Jul 7, 2012·Journal of Epidemiology and Community Health·Thomas PlougJohn Brodersen
Nov 3, 2012·Lancet·UNKNOWN Independent UK Panel on Breast Cancer Screening
Jan 25, 2013·BMJ : British Medical Journal·Jolyn HerschKirsten McCaffery
Jan 1, 2014·JAMA Internal Medicine·H Gilbert Welch, Honor J Passow
Apr 18, 2014·The New England Journal of Medicine·Nikola Biller-Andorno, Peter Jüni
May 13, 2014·South Asian Journal of Cancer·Sushma Agrawal
Jun 2, 2014·European Journal of Epidemiology·Bjorn Hofmann
Jun 3, 2014·Surgical Oncology Clinics of North America·Kristen A Ban, Constantine V Godellas
Nov 20, 2014·JAMA Surgery·Kristy L KummerowMary A Hooks
Dec 24, 2014·British Journal of Cancer·J WallerJ Wardle
Jun 21, 2015·American Journal of Preventive Medicine·Stacy M CarterAlexandra Barratt
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Oct 27, 2015·Journal of Women's Health·John D Keen, Karsten J Jørgensen
Oct 27, 2015·JAMA : the Journal of the American Medical Association·Evan R MyersGillian D Sanders
Nov 2, 2015·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Sigrunn DragesetKjell Underlid
Dec 20, 2015·International Journal of Cancer. Journal International Du Cancer·Julia S SistiA Heather Eliassen
Jan 13, 2016·International Journal of Cancer. Journal International Du Cancer·Sarah J O NomuraKim Robien
Jan 13, 2016·International Journal of Cancer. Journal International Du Cancer·Laureen DartoisFrançoise Clavel-Chapelon
May 7, 2016·Journal of Evaluation in Clinical Practice·Wendy A Rogers, Yishai Mintzker
May 15, 2016·Journal of Medical Ethics·Ronald Bayer, Amy L Fairchild
Jul 13, 2016·Journal of Medical Ethics·Stacy M CarterAlexandra Barratt
Sep 14, 2016·Maturitas·Meagan Brennan, Nehmat Houssami
Oct 9, 2016·The Breast : Official Journal of the European Society of Mastology·Karsten Juhl JørgensenRussell P Harris
Oct 13, 2016·The New England Journal of Medicine·H Gilbert WelchBarnett S Kramer

❮ Previous
Next ❯

Citations

May 6, 2019·Health Care Analysis : HCA : Journal of Health Philosophy and Policy·Wendy A RogersStacy M Carter
Nov 4, 2021·Radiation Protection Dosimetry·Sahand HooshmandPatrick C Brennan
Nov 16, 2021·Cancer Biotherapy & Radiopharmaceuticals·J Harvey Turner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Z Rayter, E Kutt
BMJ : British Medical Journal
Henrik Møller, Elizabeth Davies
© 2022 Meta ULC. All rights reserved